ORALLY BIOAVAILABLEβ-LACTAM/β-LACTAMASE INHIBITOR COMBINATION FOR BIODEFENSE AND PUBLIC HEALTH.

Ended Definitive Contract Awarded Last action

Contract number
HHSN272201600029C
Awardee
Awarding agency
Obligated
$48,517,079

Award facts

Opportunity
Contract value 100% obligated
$48,517,078.64 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 13 offers Basic Research
Pricing
Cost Plus Fixed Fee
Place of performance
Malvern, PA 19355, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Funding Only Action P00030 · To administrate DE-obligate unexpended and expiring fiscal year 2021 funding in accordance with 31 -$60,728
Funding Only Action P00029 -$195,932
Supplemental Agreement for work within scope P00028 $0
Funding Only Action P00027 -$94,723
Supplemental Agreement for work within scope P00026 $370,321
Supplemental Agreement for work within scope P00025 $0
Supplemental Agreement for work within scope P00024 $3,344,053
Supplemental Agreement for work within scope P00023 $0
Supplemental Agreement for work within scope P00022 $0
Supplemental Agreement for work within scope P00021 $2,284,288
Funding Only Action P00020 -$1
Exercise an Option P00019 $3,975,473
Supplemental Agreement for work within scope P00018 $0
Supplemental Agreement for work within scope P00017 $439,651
Supplemental Agreement for work within scope P00016 $0
Supplemental Agreement for work within scope P00015 $0
Supplemental Agreement for work within scope P00014 $1,926,565
Supplemental Agreement for work within scope P00013 $1,155,623
Supplemental Agreement for work within scope P00012 · The purpose of this contract is the development of a novel orally bioavailable beta-lactamase inhibitor through delivery to the government of: CMC and… $0
Supplemental Agreement for work within scope P00011 · Orally bioavailable B-lactam/B-lactamase inhibitor combination for biodefense and public health. $0
Other Administrative Action P00010 $0
Supplemental Agreement for work within scope P00009 · OT- orally bioavailable B-lactam/B-lactamase inhibitor combination for biodefense and public health. $1,369,025
Exercise an Option P00008 $7,234,848
Exercise an Option P00007 $2,522,045
Supplemental Agreement for work within scope P00006 $0
Exercise an Option P00005 $1,169,969
Funding Only Action 4 $2,828,870
Exercise an Option 3 $3,974,779
Funding Only Action 2 · Orally bioavailable B-lactam/B-lactamase inhibitor combination for biodefense and public health. $9,174,369
Other Administrative Action 1 $0
Original award $7,098,583
Show all 31

About this award

The National Institute of Allergy and Infectious Diseases awarded a $48.5 million definitive contract to Venatorx Pharmaceuticals Inc. for the development of orally bioavailable β-lactam/β-lactamase inhibitor combinations for biodefense and public health on September 19, 2016, under no set-aside.

This award is primarily an obligation action: the contract de-obligates unexpended and expiring fiscal year 2021 funding in accordance with 31 U.S.C. Section 1552(a), with an ultimate completion date of March 31, 2026. Place of performance is Malvern, PA. The contract is priced on a cost-plus-fixed-fee basis.

Service Contract Inventory reporting shows the contract's labor footprint contracted significantly over its performance period. FY2021 invoiced $7.9 million across 6.7 FTEs and 13,832 contractor hours. By FY2025, invoicing had declined to $2.1 million with 2.0 FTEs and 4,138 contractor hours. The government-paid blended hourly rate varied substantially year to year, ranging from $254.10/hr (FY2024) to $2,127.32/hr (FY2023), with an overall declining trend. In FY2025, Venatorx subcontracted 65% of contractor hours to one reported subcontractor.

Quick answers

Who was awarded contract HHSN272201600029C?

HHSN272201600029C was awarded to Venatorx Pharmaceuticals Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 19, 2016.

How much is contract HHSN272201600029C worth?

The government has obligated $48,517,079 on HHSN272201600029C.

Was contract HHSN272201600029C competed?

The extent of competition for HHSN272201600029C was full and open competition. The government received 13 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award